1 completed, 1 terminated. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 1, Terminated 1 |
Follow cobitolimod: new trials by email Literature Review of cobitolimod trials Research Report on cobitolimod
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis Cobitolimod 250 mg, Cobitolimod 500 mg, Placebo - Ulcerative Colitis | Phase 3 | Terminated | InDex Pharmaceuticals | 171 | 2021-11-24 | 2023-12-27 |
| The Efficacy and Safety of Cobitolimod (Kappaproct®) in Chronic Active Treatment Refractory Ulcerative Colitis Patients Cobitolimod, Placebo - Colitis, Ulcerative | Phase 3 | Completed | InDex Pharmaceuticals | 131 | 2011-12-01 | 2023-01-10 |
Colitis, Ulcerative (2) · Gastrointestinal Diseases (2) · Inflammatory Bowel Diseases (2)
France (2) · Germany (2) · Hungary (2) · Italy (2) · Poland (2) · United Kingdom (2) · Australia (1) · Austria (1) · Belgium (1) · Bosnia and Herzegovina (1) · Brazil (1) · Canada (1) · Croatia (1) · Czechia (1) · Denmark (1)
Christopher Hawkey, MD (1) · Raja Atreya, Professor (1)